<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02691351</url>
  </required_header>
  <id_info>
    <org_study_id>2015-11-070</org_study_id>
    <nct_id>NCT02691351</nct_id>
  </id_info>
  <brief_title>Intercontinental Cooperative Non-Hodgkin T-cell Lymphoma Prospective Registry Study</brief_title>
  <official_title>Intercontinental Cooperative Non-Hodgkin T-cell Lymphoma Prospective Registry Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The better understanding of non-Hodgkin T-cell lymphoma is essential for establishing&#xD;
      effective treatment strategy for non-Hodgkin T-cell lymphoma. Therefore, the data about&#xD;
      conical features and treatment outcomes of each subtype should be accumulated to establish&#xD;
      treatment strategy. However, the majority of previous data for non-Hodgkin T-cell lymphoma&#xD;
      was from small case series of single institute. Furthermore, as novel drugs were developed&#xD;
      for the treatment of relapsed or refractory T-cell lymphoma, the date from patients who were&#xD;
      treated with those novel drugs are especially required because their outcomes may reflect the&#xD;
      outcomes of currently available treatments. Thus, a multinational, multicenter prospective&#xD;
      registry study is needed to provide information useful for establishing treatment strategies&#xD;
      for T-cell lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Actual">September 2020</completion_date>
  <primary_completion_date type="Actual">July 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate to primary treatment and salvage treatment</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">500</enrollment>
  <condition>Non-Hodgkin T-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>non-Hodgkin T-cell Lymphoma</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Prospective Registry</intervention_name>
    <description>Survival and disease status follow-up at 1st primary treatment, 1st salvage treatment and 2nd salvage treatment&#xD;
Regimen&#xD;
Response Evaluation&#xD;
SUSAR(Suspected, Unexpected, Serious, Adverse Reaction) collection</description>
    <arm_group_label>non-Hodgkin T-cell Lymphoma</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        T-cell non-Hodgkin lymphoma&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically diagnosed Mature T-cell non-Hodgkin lymphoma based on the World Health&#xD;
             Organization classification 2008&#xD;
&#xD;
          -  Newly diagnosed patients without a previous treatment history for T-cell lymphoma or&#xD;
             relapsed/refractory T-cell lymphoma patients&#xD;
&#xD;
          -  Age â‰¥19 years&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hodgkin lymphoma&#xD;
&#xD;
          -  non-Hodgkin B-cell lymphoma&#xD;
&#xD;
          -  Immature non-Hodgkin T-cell lymphoma: Precursor T-lymphoblastic lymphoma/leukemia&#xD;
&#xD;
          -  Not understanding informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Won seog Kim, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>February 17, 2016</study_first_submitted>
  <study_first_submitted_qc>February 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2016</study_first_posted>
  <last_update_submitted>September 8, 2020</last_update_submitted>
  <last_update_submitted_qc>September 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Won Seog Kim</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

